Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis

Irena Doubelt, MD; Jason M Springer, MD, MSc; Tanaz A Kermani, MD; Antoine G Sreih, MD; Cristina Burroughs, MA; David Cuthbertson, MSc; Simon Carette, MD, MPhil; Nader A Khalidi, MD; Curry L Koenig, MD, MSc; Carol Langford, MD, MHS; Carol A McAlar, MA; Larry W Moreland, MD; Paul A Monach, MD; Dianne G Shaw, MA; Philip Seo, MD; Ulrich Specks, MD; Kenneth J Warrington, MD; Kalen Young, MA; Peter A Merkel, MD, MPH; Christian Pagnoux, MD, MSc, MPH

1Vasculitis Clinic, Mount Sinai Hospital, Toronto, ON, Canada
2Division of Rheumatology, University of Toronto, Toronto, ON, Canada
3Division of Rheumatology and Immunology, Medical Center, Vanderbilt University, Nashville, TN, United States
4Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, United States
5Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, United States
6Health Informatics Institute, University of South Florida, Tampa, FL, United States
7Division of Rheumatology, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada
8Division of Rheumatology, University of Utah Hospital, Salt Lake City, UT, United States
9Division of Rheumatology, Cleveland Clinic, Cleveland, OH, United States
10Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, United States
11Division of Rheumatology, Veterans Affairs Boston Healthcare System, Boston, MA, United States
12Vasculitis Foundation, Kansas City, MO, United States
13Division of Rheumatology, Johns Hopkins University, Baltimore, MD, United States
14Division of Pulmonary and Critical Care Medicine, College of Medicine and Science, Mayo Clinic, Rochester, MN, United States
15Division of Rheumatology, College of Medicine and Science, Mayo Clinic, Rochester, MN, United States
16Vasculitis Clinical Research Consortium and Vasculitis Patient-Powered Research Network

Corresponding Author:
Christian Pagnoux, MD, MSc, MPH
Vasculitis Clinic
Mount Sinai Hospital
60 Murray Street, Ste 2-220, Box 8
Toronto, ON, M5T 3L9
Canada
Phone: 1 416 586 4800 ext 8549
Email: christian.pagnoux@sinaihealth.ca

Abstract

Background: Patient-based registries can help advance research on rare diseases such as eosinophilic granulomatosis with polyangiitis (EGPA), a complex multiorgan form of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Objective: The aim of this study is to compare patient-reported and physician-reported data on manifestations, treatments, and outcomes for patients with EGPA.

Methods: We completed a comparative analysis of patients ≥18 years with EGPA in Canada and the United States from the following 2 cohorts: (1) The Vasculitis Patient-Powered Research Network (VPPRN), a self-enrolled secure portal with patient-entered data updated quarterly (2014-2019) and (2) the Vasculitis Clinical Research Consortium (VCRC) observational studies, a physician-entered database (2003-2019) of patients who fulfilled the 1990 American College of Rheumatology classification criteria for EGPA. The studied parameters included demographic characteristics, clinical manifestations, ANCA status, treatments, and relapses.
**Results:** Data from 195 patients with a validated diagnosis of EGPA in the VPPRN and 354 patients enrolled in the VCRC were analyzed. Compared to the VCRC cohort, the patients in the VPPRN cohort were more likely to be female (135/195, 69.2% compared to 209/354, 59%; P=0.02) and younger at diagnosis (47.3 compared to 50.0 years; P=0.03); both cohorts reported similar frequencies of asthma (177/184, 96.2% in the VPPRN cohort compared to 329/354, 92.9% in the VCRC cohort; P=0.13) and cardiac manifestations (44/153, 28.8% compared to 75/354, 21.2%; P=0.06), but the VPPRN cohort reported less frequent lung manifestations other than asthma and more frequent disease manifestations in all other organ systems. The ANCA positivity was 48.9% (64/131) in the VPPRN patients compared to 38.9% (123/316; P=0.05) in the VCRC cohort. Relapsing disease after study enrollment was reported in 32.3% (63/195) of patients in the VPPRN compared to 35.7% (99/277) of patients in the VCRC. Most therapies (GC, cyclophosphamide, mepolizumab) were used at similar frequencies in both groups, except for rituximab with VPPRN patients reporting more use than the VCRC cohort (47/195, 24.1% compared to 29/277, 10.5%; P<0.001).

**Conclusions:** Overall, patients and physicians report manifestations of EGPA at similar frequencies. However, observed differences between patient and physician reports imply the potential occurrence of selection biases. These results support the use of patient-reported data in EGPA but also the need for careful consideration of disease-specific definitions for the study of EGPA and how patient- and physician-reported data are collected.

**Trial Registration:** ClinicalTrials.gov NCT00315380, https://clinicaltrials.gov/ct2/show/NCT00315380; ClinicalTrials.gov NCT01241305, https://clinicaltrials.gov/ct2/show/NCT01241305

---

**KEYWORDS**
eosinophilic granulomatosis with polyangiitis; patient-reported outcomes measures; clinical outcomes; granulomatosis; patient outcomes; digital health; health network; health databases; research network

---

**Introduction**

Vasculitides are rare, heterogeneous, multisystem diseases causing inflammation of blood vessels [1]. Physicians determine disease activity, damage, and prognosis in vasculitis using various clinical, laboratory, or radiological parameters or tools, such as the Birmingham Vasculitis Activity Score [2] or the Vasculitis Damage Index [3]. Many of these parameters may at times differ from the patient’s subjective disease experiences. There is growing interest in increasing patient engagement in health care research to improve the alignment of patients’ and physicians’ perspectives in the diagnosis, management, and assessment of outcomes and burden of disease; more and more action has been taken to achieve this. [4].

The Vasculitis Patient-Powered Research Network (VPPRN), an international, internet-based, prospective longitudinal registry of patient- or caregiver-reported data, was launched in 2014 to support people with any form of vasculitis by involving them in clinical research [4-6]. With over 3000 members enrolled to date, mostly from North America, it maintains a secure web-based registry where patients provide clinical data about themselves and their condition regarding demographic characteristics, diagnosis, disease extent, medications, and outcomes [4].

The Vasculitis Clinical Research Consortium (VCRC), established in 2003, has been collecting longitudinal data in patients with various vasculitides across 8 US and 2 Canadian sites. VCRC site investigators collected similar clinical information as the VPPRN.

This study aimed to compare patient self-reported and physician-reported clinical manifestations, treatments, and outcomes in patients with eosinophilic granulomatosis with polyangiitis (EGPA), one of the antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. EGPA is a complex multisystem disorder that can involve any combination of many manifestations, especially including asthma, rhinosinusitis, eosinophilia, and vasculitis in various organs. Research on EGPA has not been as extensively conducted compared to several other forms of vasculitis. A better understanding of the utility of patient-based research registries could help advance research on this rare disease.

**Methods**

**Vasculitis Patient-Powered Research Network: Patient-Driven Cohort**

The VPPRN provides a secure portal through which patients self-enroll and self-report information longitudinally using the internet-based platform, as previously described [6]. Data from patients in the VPPRN (2014-2019) who self-identified as being age 18 years or older, living in Canada or the United States, and having EGPA were used for this analysis. For validation of the diagnosis, patients were excluded if they indicated that the diagnosis of EGPA was not made by a doctor and/or if they reported never having used systemic glucocorticoids (GC).

Standardized questions were used to obtain data on demographic characteristics (age, sex, ethnicity), signs and symptoms of vasculitis at any time after disease onset, diagnostic tests, prescribed treatments, and outcomes from patients, with quarterly updates by email reminders. Questions related to disease manifestations were asked using lay terms, as listed in Table 1. Patients could select responses of yes, no, or I don’t know; blank responses were excluded from the data analysis.

**Vasculitis Clinical Research Consortium: Physician-Driven Cohort**

Data from patients with EGPA entered into the VCRC database, as part of either the VCRC Longitudinal Study (LS; NCT00315380) [7] or the One-Time DNA (OT) Study

---

**Table 1. Patients could select responses of yes, no, or I don’t know; blank responses were excluded from the data analysis.**

**Vasculitis Damage Index**

**Birmingham Vasculitis Activity Score**

**Relapsing disease after study enrollment**

**Vasculitis Patient-Powered Research Network (VPPRN)**

**Vasculitis Clinical Research Consortium (VCRC)**

**ClinicalTrials.gov NCT00315380, https://clinicaltrials.gov/ct2/show/NCT00315380; ClinicalTrials.gov NCT01241305, https://clinicaltrials.gov/ct2/show/NCT01241305

---

**Interact J Med Res 2022;11(1):e27273** doi: 10.2196/27273

---

https://www.i-jmr.org/2022/1/e27273

Interact J Med Res 2022 | vol. 11 | iss. 1 | e27273 | p. 2

(page number not for citation purposes)
(NCT01241305; conducted 2013-2019) [8], were used for this analysis. Patients were ages 18 years or older at enrollment and met the 1990 American College of Rheumatology classification criteria for EGPA [9]. In the VCRC-LS observational cohort, participants had in-person assessments with site investigators at either quarterly or annual visits, based on each patient’s preference and availability, with data collection of clinical and laboratory information. Patients in the VCRC-OT were assessed only at a single study visit (at diagnosis or later). All study visits involved the completion of standardized forms that collected information on patient demographic characteristics, disease characteristics, relapse(s) prior to enrollment, and, for LS only, treatments received, relapses after enrollment, and disease-related damage (from the disease itself or treatment).

Patients may be enrolled in both databases (VPPRN and VCRC); however, at present, to comply with regulations protecting health information, the databases are not linked.

**Data Elements**

Demographic characteristics, main clinical manifestations of EGPA (from disease diagnosis to data extraction), ANCA status, follow-up duration, relapses (from diagnosis and/or after enrollment), and all treatments ever received (GC and other immunosuppressive drugs) were analyzed for both cohorts.

**Ethics Approval**

The VCRC study protocols were approved by the local hospital research ethics board committees at all participating VCRC sites. The VPPRN data collection protocol was approved by the institutional review board at the University of South Florida (Pro00018514_CR000001). All subjects in both the VCRC and VPPRN provided consent for their participation prior to enrollment. All research was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki.

**Statistical Analyses**

Descriptive statistics were computed by calculating the mean and SD for quantitative variables and count (percent) for categorical variables. Quantitative variables were compared using unequal variances t tests; categorical variables were compared using chi-square tests. Statistically significant differences were defined as those with $P$ values $\leq 0.05$. Statistical analyses were performed using Stata (version 12; StataCorp).

**Results**

**Vasculitis Patient-Powered Research Network: Patient Characteristics**

At the time of data extraction, a total of 208 patients were registered in the VPPRN with a diagnosis of EGPA. A total of 13 patients were excluded as they indicated they had not been diagnosed by a doctor and/or had never been treated with systemic GC. Of the final 195 patients, 69.2% (n=135) were female; the average age at diagnosis was 47.3 years; 176 (90.3%) were White, 4 (2.1%) were Asian, and 1 (0.5%) was Black or African American. Additional cohort-specific details are presented in Table 1.

For the 195 patients, the methods by which their diagnoses of EGPA were determined comprised of the following: symptoms (n=178, 91.3%), laboratory testing (n=157, 80.5%), biopsy results (n=98, 50.3%), and imaging (n=98, 50.3%).

**Vasculitis Clinical Research Consortium: Patient Characteristics**

At the time of data extraction, the VCRC cohort included 354 patients (277 LS and 77 OT). Of the 354 patients, 59% (n=209) were female; the average age at diagnosis was 50.0 years; 309 (87.3%) were White, 20 (5.6%) were Asian, and 7 (2%) were Black or African American. Additional cohort-specific details are presented in Table 1.

**Comparisons Between Patients with EGPA in the VPPRN and VCRC**

Comparisons of demographic characteristics, ANCA status, clinical manifestations (from disease diagnosis to data extraction), relapses, and all treatments ever used for patients in the VPPRN and VCRC are shown in Table 1. Compared to the patients in the VCRC, patients in the VPPRN were younger at the time of diagnosis and reported similar frequencies of asthma and cardiac manifestations, less frequent lung manifestations other than asthma, and more frequent disease manifestations in all other organ systems. Relapse rates post enrollment were similar between the 2 cohorts.
| Characteristics                              | VPPRN\(^a\) cohort (N=195) | VCRC\(^b\) cohort (N=354) | \(P\) value |
|--------------------------------------------|------------------------------|----------------------------|-------------|
| **Sex, n (%)**                             |                              |                            |             |
| Female                                     | 135 (69.2)                   | 209 (59)                   | .02         |
| Male                                       | 60 (30.8)                    | 145 (40.9)                 | .02         |
| **Age at diagnosis in years, mean (SD)**   |                              |                            |             |
|                                            | 47.3 (14.3)                  | 50.0 (14.2)                | .03         |
| **Positive test for ANCA\(^c\), n (%)\(^d\)**|                              |                            | .05         |
| **Manifestations, n (%)\(^e,f\)**          |                              |                            |             |
| Asthma                                     | 177 (96.2)                   | 329 (92.9)                 | .13         |
| Coughed up blood or bleeding in the lungs/alveolar hemorrhage | 24 (14.4) | 21 (5.9) | .001 |
| Problems with your lungs/lung involvement  | 126 (72.4)                   | 296 (83.6)                 | .003        |
| Problems with your nose or sinuses/nasal involvement | 165 (92.2) | 292 (82.5) | .003 |
| Fever                                      | 82 (55.4)                    | 62 (17.5)                  | <.001       |
| Weight loss                                | 95 (55.6)                    | 106 (29.9)                 | <.001       |
| Severe joint pain or swelling/arthralgia(s) | 116 (67.1)                   | 140 (39.5)                 | <.001       |
| Rash/skin                                  | 125 (70.6)                   | 106 (29.9)                 | <.001       |
| Inflammation of the heart lining/cardiac   | 44 (28.8)                    | 75 (21.2)                  | .06         |
| Problems with your kidneys/renal disease   | 39 (22.4)                    | 36 (10.2)                  | <.001       |
| Numbness, tingling, trouble moving arms, hands, legs, or feet, or other forms of nerve damage/neurological | 155 (87.6) | 214 (60.5) | <.001 |
| Inflammation in one or both eyes that required treatment/eye disease | 42 (26.1) | 31 (8.8) | <.001 |
| Loss of blood supply to intestines or perforation/mesenteric ischemia | 10 (6.1) | 7 (2) | .02 |
| Thrombosis                                 | 24 (14)                      | 24 (6.8)                   | .007        |
| **Follow-up time in years, mean (SD)**     |                              |                            |             |
| From diagnosis                             | 8.0 (6.8)                    | 7.0 (6.2)                  | .08         |
| From enrollment                            | 2.2 (1.1)                    | 3.6 (3.5)                  | <.001       |
| **Relapses, n (%)**                        |                              |                            |             |
| Total since diagnosis                      | N/A                          | 175 (49.4)                 | N/A\(^f\)  |
| After enrollment                           | 63 (32.3)                    | 99 (35.7)\(^h\)           | .44         |
| Deaths, n (%)                              | 0 (0)\(^j\)                  | 11 (4)\(^h\)               | N/A         |
| **Treatments ever received, n (%)\(^j\)**  |                              |                            |             |
| Systemic glucocorticoids                   | 195 (100)                    | 354 (100)                  | .99         |
| Cyclophosphamide                           | 79 (40.5)                    | 115 (41.5)\(^h\)          | .83         |
| Mepolizumab                                | 20 (10.3)                    | 25 (9)\(^h\)              | .65         |
| Rituximab                                  | 47 (24.1)                    | 29 (10.5)\(^h\)           | <.001       |

\(^a\) VPPRN: Vasculitis Patient-Powered Research Network.

\(^b\) VCRC: Vasculitis Clinical Research Consortium.

\(^c\) ANCA: antineutrophil cytoplasmic antibody.

\(^d\) For this category, N=131 for the VPPRN cohort and N=316 for the VCRC cohort. Percentages have been calculated accordingly.

\(^e\) For the VPPRN cohort, the N value for each category is the number of patients who responded yes or no (the response of “I don’t know” was excluded). The N values are as follows: asthma (N=184); coughed up blood or bleeding in the lungs (N=166); problems with your lungs (N=174); problems with your nose or sinuses (N=179); fever (N=148); weight loss (N=171); severe joint pain or swelling (N=173); rash (N=177); inflammation of the heart lining (N=153); problems with your kidneys (N=174); numbness, tingling, trouble moving arms, hands, legs, or feet, or other forms of nerve damage (N=177); Inflammation in one or both eyes that required treatment (N=161); loss of blood supply to intestines or perforation (N=165); thrombosis...
(N=171). The percentages have been calculated accordingly.

For this category, some items are presented as follows: phrasing in VPPRN database/phrasing in VCRC database.

N/A: not applicable.

Data were available for 277 patients in the VCRC–Longitudinal Study (VCRC-LS). These percentages have been calculated accordingly.

All patients in the VPPRN logged into the portal and completed at least 1 form within 24 months prior to data extraction with none documented as lost to follow-up; captured follow-up losses and deaths in VPPRN are limited due to the inherent nature of the study design (privacy concerns associated with contacting treating physicians, family members, etc.). Additional treatments for patients in the VCRC-LS (N=277) included azathioprine (n=145, 52.3%), methotrexate (n=109, 39.4%), and mycophenolate mofetil (n=25, 9%).

Discussion

Principal Findings

In this study, we compared patient-reported and physician-reported outcomes in 2 cohorts of patients with EGPA: both patients and physicians reported a spectrum of outcomes and relative frequencies of manifestations, relapse rates, and medication use that are quite consistent with what is expected for this heterogeneous multisystem disease. However, some interesting differences in how this disease was reported were also observed between the 2 cohorts, raising the possibility of selection biases impacting data collection in these 2 registries.

With the exception of asthma and cardiac involvement, patients reported, for example, higher frequencies of almost all manifestations of EGPA compared to physicians. These differences could be due to any combination of several reasons, including the following: (1) patients over-report manifestations, some of which may not be due to EGPA; (2) physicians under-report manifestations and/or do not validate patients’ reports of problems prior to evaluating them; (3) patients and physicians have a different understanding of specific manifestations; and (4) the VPPRN and VCRC involved 2 separate cohorts due to selection and inclusion biases.

Whereas the 2 cohorts did appear similar overall to what is expected for a large group of patients with EGPA, it is possible that the patients in the VPPRN had, at least initially, more severe disease or a different disease phenotype. The VPPRN cohort had a higher proportion of ANCA-positive patients, who were shown in a few previous cohort studies to present more often with surrogates of vasculitis, such as renal or cutaneous involvement [10-13]. ANCA-positive patients may also be treated with rituximab more frequently compared to the ANCA-negative EGPA population. Due to regulations protecting health information, direct linkage and comparisons of the patient-reported and physician-reported data for those “shared” participants (patients enrolled in both studies regardless of ANCA status) were not possible.

Certain subgroups may have been overrepresented due to biased sampling, as in other patient-driven registries. The mode of survey via internet-based participation for the VPPRN cohort may have enrolled more younger and female patients and more patients with ready access to the internet [14]. Such distinctions in patient- and physician-based disease features have also been observed in other rheumatic conditions [15-18]. However, previous studies using data in the VPPRN on the 2 other types of ANCA-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) provided evidence for the clinical validity of the VPPRN data, thus the likely limited impact of any selection biases [6].

Misinterpretation or the use of different definitions of disease manifestations may also have contributed to some differences or inaccurate results in both cohorts. For instance, almost all patients with EGPA have asthma, whereas 70-80% of patients responded yes to “problems with [your] lungs/ lung involvement.” Asthma is considered a comorbidity or underlying manifestation of EGPA. For disease scoring and in studies on EGPA, “lung manifestations” thus usually involve other nonasthma symptoms or manifestations, separately, such as lung infiltrates, nodules, or alveolar hemorrhage. This distinction is not always applied by physicians in studies and may be even more difficult to understand by patients. The way data and information are collected in registries is crucial and clear wording is essential to deal with such aspects of the disease, especially for studies with patient-reported data. Investigators should consider all these factors when researching EGPA, both through internet-based mechanisms and traditional clinic-based approaches.

This study provides new and valuable information from both a patient and physician perspective and has several notable strengths including the sizes of the geographically diverse study cohorts, the extent of the data, overlapping leadership of the 2 research cohorts, and the long duration of follow-up for data collection. Highly experienced investigators in the field of vasculitis selected, designed, and collected the data elements using standardized forms in the VCRC and VPPRN cohorts, and patients had direct input during each stage of the process for the development of the VPPRN forms.

Conclusions

There is a clear mandate and many benefits for health care professionals to incorporate patient perspectives into the assessment and management of vasculitis [19]. How patients’ perspectives may correspond to physicians’ assessments remains a subject of study and uncertainty. This study comparing patient-reported and physician-reported characteristics and outcomes in patients with EGPA should encourage rethinking and refinement of how patients are recruited and how their data are collected for complex diseases. These results support the use of patient-reported data in EGPA but also the need for careful consideration of these 2 types of registries, how patient- and physician-reported data are collected, as well as disease-specific definitions for the study of EGPA. Establishing a common set of disease-specific items and outcomes in EGPA and using similar definitions or wording is advised when seeking to combine data from both patients and physicians.
Acknowledgments

The VPPRN has received support from the Patient-Centered Outcomes Research Institute (grant PPRN-1306-04758) and the VCRC. The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research at the National Center for Advancing Translational Science (NCATS). The VCRC has received funding from the NCATS, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant U54 AR057319), the National Center for Research Resources (grant U54 RR019497), and GlaxoSmithKline plc.

Authors’ Contributions

All authors were involved in substantial contributions to study conception and design, acquisition of data, and approval of the final manuscript version. ID, CB, DC, PA Merkel, and CP had full access to the data in the study and take responsibility for the integrity of the data, accuracy of the data analysis, data interpretation, and drafting of the article.

Conflicts of Interest

CP reports receiving fees for serving on advisory boards for ChemoCentryx Inc, GlaxoSmithKline plc, Sanofi SA, F. Hoffman-La Roche AG, InflaRx GmbH, and AstraZeneca plc; he also reports receiving lecture fees and research grant support from F. Hoffman-La Roche AG and GlaxoSmithKline plc. PA Merkel reports receiving funds for the following activities in the past 2 years: consulting for AbbVie Inc, AstraZeneca plc, Biogen Inc, Boehringer Ingelheim, Bristol Myers Squibb Co, Celgene Corp, ChemoCentryx Inc, CSL Behring, Dynacure SA, EMD Serono, Forbius, Genentech Inc/F. Hoffman-La Roche AG, Genzyme Corp/Sanofi SA, GlaxoSmithKline plc, InflaRx GmbH, Insmed Inc, Janssen Inc, Kiniksa Pharmaceuticals Ltd, Kyverna Therapeutics Inc, Magenta Therapeutics Inc, Neutrolis Inc, Novartis AG, Pfizer Inc, Sparrow Pharmaceuticals Inc, Takeda Pharmaceutical Company Ltd, Talaris Therapeutics Inc; research support from AbbVie Inc, AstraZeneca plc, Boehringer Ingelheim, Bristol Myers Squibb Co, Celgene Corp, ChemoCentryx Inc, Eicos, Forbius, Genentech Inc/F. Hoffman-La Roche AG, Genzyme Corp/Sanofi SA, GlaxoSmithKline plc, InflaRx GmbH, Sanofi SA, and Takeda Pharmaceutical Company Ltd; and royalties from UpToDate Inc. AGS is an employee of Bristol Myers Squibb Co. NAK is part of the advisory board/speaker bureau at F. Hoffman-La Roche AG and also receives research grant support from F. Hoffman-La Roche AG, Bristol Myers Squibb Co, Sanofi, AbbVie Inc, and AstraZeneca plc.

References

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013 Jan;65(1):1-11 [FREE Full text] [doi: 10.1002/art.37715] [Medline: 23045170]
2. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009 Dec;68(12):1827-1832. [doi: 10.1136/ard.2008.101279] [Medline: 19054820]
3. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997 Feb;40(2):371-380. [doi: 10.1002/art.1780400222] [Medline: 9041949]
4. Young K, Kaminstein D, Olivos A, Burroughs C, Castillo-Lee C, Kullman J, Vasculitis Patient-Powered Research Network, et al. Patient involvement in medical research: what patients and physicians learn from each other. Orphanet J Rare Dis 2019 Jan 24;14(1):21 [FREE Full text] [doi: 10.1186/s13023-018-0969-1] [Medline: 30678705]
5. PCORnet PPRN Consortium, Daugherty SE, Wahba S, Fleurence R. Patient-powered research networks: building capacity for conducting patient-centered clinical outcomes research. J Am Med Inform Assoc 2014;21(4):583-586 [FREE Full text] [doi: 10.1136/amiq-2014-002758] [Medline: 24821741]
6. Springer JM, Kermani TA, Sreih A, Shaw DG, Young K, Burroughs CM, et al. Clinical characteristics of an internet-based cohort of patient-reported diagnosis of granulomatosis with polyangiitis and microscopic polyangiitis: observational study. J Med Internet Res 2020 Jul 20;22(7):e17231 [FREE Full text] [doi: 10.2196/17231] [Medline: 32459634]
7. Longitudinal study for eosinophilic granulomatosis with polyangiitis (Churg-Strauss). ClinicalTrials.gov. URL: https://clinicaltrials.gov/ct2/show/record/NCT00315380?view=record [accessed 2022-03-22]
8. One-time DNA study for vasculitis. ClinicalTrials.gov. URL: https://clinicaltrials.gov/ct2/show/NCT01241305 [accessed 2022-03-22]
9. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990 Aug;33(8):1094-1100. [doi: 10.1002/art.1780330806] [Medline: 2203207]
10. Cottin V, Bel E, Bottero P, Dalhoff K, Humbert M, Lazor R, Groupe d’Etudes et de Recherche sur les Maladies Orphelines Pulmonaires (GERM“O”P). Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): a study of 157 patients by the Groupe d’Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
Autoimmun Rev 2017 Jan;16(1):1-9. [doi: 10.1016/j.autrev.2016.09.018] [Medline: 27671089]

11. Sablé-Fourtassou R, Cohen P, Mah R, Pagnoux C, Mouthon L, Jayne D, French Vasculitis Study Group. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005 Nov 01;143(9):632-638. [doi: 10.7326/0003-4819-143-9-20051110-00006] [Medline: 16263885]

12. Comarmond C, Pagnoux C, Khellaf M, Cordier J, Hamidou M, Viallard J, French Vasculitis Study Group. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013 Jan;65(1):270-281 [FREE Full text] [doi: 10.1002/art.37721] [Medline: 23044708]

13. Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005 Sep;52(9):2926-2935 [FREE Full text] [doi: 10.1002/art.21250] [Medline: 16142760]

14. Abdou NI, Kullman GJ, Hoffman GS, Sharp GC, Specks U, McDonald T, et al. Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol 2002 Feb;29(2):309-316. [Medline: 11838848]

15. Tomasson G, Farrar JT, Cuthbertson D, McAlear CA, Ashdown S, Cronholm PF, Vasculitis Clinical Research Consortium. Feasibility and construct validation of the patient reported outcomes measurement information system in systemic vasculitis. J Rheumatol 2019 Aug;46(8):928-934 [FREE Full text] [doi: 10.3899/jrheum.171405] [Medline: 30824648]

16. Kirwan JR, Boonen A, Harrison MJ, Hewlett SE, Wells GA, Singh JA, et al. OMERACT 10 Patient Perspective Virtual Campus: valuing health; measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in health. J Rheumatol 2011 Aug;38(8):1728-1734. [doi: 10.3899/jrheum.110393] [Medline: 21807793]

17. Hewlett S, Sanderson T, May J, Alten R, Bingham CO, Cross M, et al. 'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count--an international patient perspective on flare where medical help is sought. Rheumatology (Oxford) 2012 Jan;51(1):69-76. [doi: 10.1093/rheumatology/kek455] [Medline: 21565901]

18. Neogi T, Xie H, Felson DT. Relative responsiveness of physician/assessor-derived and patient-derived core set measures in rheumatoid arthritis trials. J Rheumatol 2008 May;35(5):757-762 [FREE Full text] [Medline: 18412313]

19. Robson JC, Jayne D, Merkel PA, Dawson J. Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes. Patient Relat Outcome Meas 2019;10:37-42 [FREE Full text] [doi: 10.2147/PROM.S163601] [Medline: 3084691]

Abbreviations

ANCA: antineutrophil cytoplasmic antibody
EGPA: eosinophilic granulomatosis with polyangiitis
GC: glucocorticoids
LS: longitudinal study
NCATS: National Center for Advancing Translational Science
OT: one-time DNA
VCRC: Vasculitis Clinical Research Consortium
VPPRN: Vasculitis Patient-Powered Research Network

©Irena Doubelt, Jason M Springer, Tanaz A Kermani, Antoine G Sreih, Cristina Burroughs, David Cuthbertson, Simon Carette, Nader A Khalidi, Curry L Koenig, Carol Langford, Carol A McAlear, Larry W Moreland, Paul A Monach, Dianne G Shaw, Philip Seo, Ulrich Specks, Kenneth J Warrington, Kalen Young, Peter A Merkel, Christian Pagnoux. Originally published in the Interact J Med Res 2022 | vol. 11 | iss. 1 | e27273 | p. 7 https://www.i-jmr.org/2022/1/e27273 doi: 10.2196/27273 PMID:
